The commissioned development and production services of CDMO include cell line development, process development and amplification, development and validation of analytical methodology, product identification, GMP production and stability tests for clinical trials, and CMC (chemical, manufacturing, and control). The development of biosimilars is based on reverse engineering technology. Among the products, EG12014 completed its global clinical test in March 2021, and the analysis results reached the bioequivalence standard.